详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Multicenter phase II study of moderate low-dose radiotherapy in indolent non-Hodgkin lymphoma: CLCG-iNHL-01 protocol

1| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Off Canc Screening,, Beijing 100021, Peoples R China [3]Capital Med Univ, Beijing TongRen Hosp, Dept Hematol, Beijing 100730, Peoples R China [4]Fujian Med Univ, Union Hosp, Dept Radiat Oncol, Fuzhou 350108, Fujian, Peoples R China [5]Shanxi Med Univ, Shanxi Canc Hosp, Taiyuan 030013, Shanxi, Peoples R China [6]Shanxi Med Univ, Affiliated Canc Hosp, Taiyuan 030013, Shanxi, Peoples R China [7]Ningbo Univ, Affiliated Peoples Hosp, Dept Radiochemotherapy, Ningbo 315100, Zhejiang, Peoples R China [8]Beijing Hosp, Natl Geriatr Med Ctr, Dept Radiat Oncol, Beijing 100005, Peoples R China [9]Capital Med Univ, Beijing Luhe Hosp, Dept Radiotherapy, Beijing 101199, Peoples R China [10]Chinese Acad Med Sci CAMS & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing 100021, Peoples R China [11]Chinese Acad Med Sci CAMS & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Pathol, Beijing 100021, Peoples R China

出处：

DOI：

ISSN：

关键词： hypofractionation indolent lymphoma low-dose radiotherapy

摘要：

Background: Radiotherapy is an effective treatment for indolent non-Hodgkin lymphoma (iNHL); however, the optimal radiotherapy dose remains to be determined. We hypothesize that a suitable dose may exist between 4 and 24 Gy. Methods: This prospective multicenter phase II trial intends to recruit 73 sites of iNHL patients, who will receive involved-site radiotherapy of 12 Gy in four fractions. The primary objective is the 6-month clinical complete response rate. Tumor tissue, blood and conjunctival specimens will be collected to identify potential predictive biomarkers. Discussion: The CLCG-iNHL-01 trial will evaluate the efficacy and toxicity of 12 Gy in patients with iNHL and provide information on a novel hypofractionation regimen of low-dose radiotherapy.Clinical Trial Registration: NCT05543070 (ClinicalTrials.gov)

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2022]版：

Q3 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3 最新[2023版] 2.9 最新五年平均 3.3 出版当年[2022版] 3.2 出版当年五年平均 3.674 出版前一年[2021版] 3 出版后一年[2023版]

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing 100021, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors [2]Initial Results of the Multicenter Phase II Trial of a Novel Hypofractionated Low-Dose Radiotherapy for Indolent Non -Hodgkin Lymphoma [3]Low-dose Radiotherapy in iNHL [4]Tumor Response in Hypofractionated Radiotherapy [5]All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. [6]Efficacy and Mechanism of Hypofractionation Radiotherapy Combined with PD-1 Inhibitors in a Model of Head and Neck Melanoma [7]Low dose reconstruction algorithm for differential phase contrast imaging [8]Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention [9]All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. [10]All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP